Press Releases from XL-protein GmbH (6 total)
XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting P …
SAN DIEGO, U.S.A., and FREISING, Germany, 15th October, 2020: Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH,…
XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel In …
Freising, Germany and San Diego, CA, February 25, 2020 -- XL-protein has extended its existing partnership with DNX Biopharmaceuticals, a biopharmaceutical company developing nonimmunogenic, long-acting…
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharm …
New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology
Irvine, CA and…
YEDA and XL-protein sign business collaboration agreement to commercialize PASyl …
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014:
Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and…
XL-protein announces publication of key scientific data on its PASylation techno …
FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced today that key scientific data have been published in the journal Protein Engineering, Design & Selection…
XL-protein announces preclinical in vitro and in vivo data for its PASylated hum …
FREISING, GERMANY, September 23, 2011 – XL-protein GmbH, a German biotech company specialised in the development of biopharmaceuticals with extended plasma half-life, announced today preclinical…
Go To Page:
